偏小剂量的硼替佐米联合地塞米松治疗初发多发性骨髓瘤疗效观察  

The Efficacy of Small Doses of Bortezomib and Dexamethasone Treating on Newly Multiple Myeloma

作　　者：苏基滢[1] 周立宇[1] 徐黎[1] 宋陆茜[1] 张曦[1] 肖超[1] 常春康[1] 

机构地区：[1]上海交通大学附属上海市第六人民医院血液科,上海200233

出　　处：《癌症进展》2012年第1期80-83,共4页Oncology Progress

摘　　要：目的每次1.75 mg(0.8～1.0 mg/m2)的硼替佐米联合地塞米松对初发多发性骨髓瘤疗效观察。方法17例初发患者接受硼替佐米+地塞米松的方案治疗。硼替佐米每次1.75 mg(0.8～1.0 mg/m2),第1、4、8、11天,3～5秒内静脉推注完成;地塞米松20 mg/d,第1、2、4、5、8、9、11、12天静脉滴注,同时地塞米松0.75mg/d,口服,第1～12天。21天为1个疗程。完成4个疗程。结果完成4个疗程偏小剂量硼替佐米结合地塞米松治疗的初发多发性骨髓瘤患者的有效率为88.23%。高于传统VAD化疗方案的有效率(44.74%),且两者有统计学差异;不低于推荐剂量(1.3 mg/m2)的硼替佐米方案治疗的有效率。结论偏小剂量硼替佐米联合地塞米松对初发多发性骨髓瘤治疗仍有较好疗效,但其对疗效维持的长久性尚需进一步随访观察。Objective To observe the effect of 1.75rag （about 0. 8 - 1.0mg/m2） bortezomib and dexamethasone every time treating on the newly multiple myeloma （MM） patients. Methods 17 patients received the treatment of bort- ezomib （ 1.75rag, about 0. 8 - 1.0mg/m2, every time, on day 1, 4, 8, 11, intravenous injection within 3-5 seconds） and dexamethasone （20mg intravenous infusion every day, on day 1, 2, 4, 5, 8, 9, 11, 12, and 0. 75rag oral every day, from day 1 to 12）, with 21 days as a course. All the patients had completed 4 courses. Result The effective rate of the newly MM patients who had received 4 courses treatment of small doses of bortezomib and dexamethasone was 88.23% , which was higher than the traditional chemotherapy regimen （VAD）, whose effective rate was 44. 74%. There were significant differences between the two regimens. And it was not less than the effective rate of the recommended dose of bortezomib （ 1.3 mg/m2 ）. Conclusion Small doses of bortezomib and dexamethasone treating newly multiple myeloma also show a good therapeutic effect but its long-term maintenance of efficacy needs further follow-up observation.

关 键 词：硼替佐米 多发性骨髓瘤 初发 

分 类 号：R730.53[医药卫生—肿瘤] R738.1[医药卫生—临床医学]